Eli Lilly Soars Past Q2 Estimates Driven by Blockbuster Weight-Loss and Diabetes Drugs; Raises Full-Year Outlook

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter, significantly exceeding Wall Street expectations for both earnings and revenue. The pharmaceutical giant also announced an optimistic upward revision of its full-year sales outlook, largely propelled by the surging demand for its highly successful weight-loss drug Zepbound and diabetes treatment Mounjaro. This performance marks a pivotal moment, including the first earnings report to incorporate sales from Lilly's newly launched obesity pill, Foundayo.

The company now forecasts its 2026 revenue to fall within the range of $85 billion to $87 billion, an increase from its prior guidance of $82 billion to $85 billion. This projection underscores the robust growth trajectory driven by Lilly's innovative drug portfolio.

Eli Lilly CEO Dave Ricks expressed considerable enthusiasm in a CNBC interview, stating, "It's a really strong start to the year for Lilly… it's hard to think of a time that we've been in a better position than this." The company's Q2 performance highlights its dominant position in the rapidly expanding market for GLP-1 drugs, capturing a significant 60.9% share of the U.S. obesity and diabetes drug market in the second quarter, outpacing competitor Novo Nordisk.

Key Financial Highlights for Q2:

• Adjusted Earnings Per Share (EPS): $8.38, surpassing the Wall Street consensus of $6.01.
• Revenue: $22.97 billion, exceeding the expected $20.73 billion.

The robust sales figures for Mounjaro and Zepbound have been instrumental in Lilly's strong quarterly results. Mounjaro's worldwide revenue experienced a remarkable 91% increase, reaching $9.94 billion, with U.S. sales contributing $4.8 billion. Notably, international sales for Mounjaro surged by 172%, indicating strong global adoption, particularly in emerging markets like Brazil, China, and India, where out-of-pocket payments are driving durable demand.

Zepbound, a key player in the weight-loss market, generated $4.93 billion in revenue for the quarter, reflecting a 46% year-over-year increase. Despite some price adjustments due to cash-pay discounts, demand for the drug remains exceptionally strong. Analysts had projected $4.69 billion in U.S. sales for Zepbound.

The recent addition of Foundayo to Lilly's portfolio has also shown promising early results. The obesity pill, which received U.S. approval in April, recorded $98 million in sales for the second quarter, aligning closely with analyst forecasts of nearly $103 million. Ricks highlighted the drug's accelerating momentum, noting a doubling of consumer awareness and prescriptions within a month of its launch.

"We're really pleased with the start; it's accelerating as we speak," Ricks commented, emphasizing the company's efforts in building physician and consumer awareness, as well as securing formulary access. He added that about a quarter of new patients initiating oral weight-loss medications are starting with Foundayo.

Lilly's strategic acquisitions also continue to shape its future. The company recently announced a deal to acquire a psychedelics drugmaker and plans to purchase three vaccine makers, signaling an aggressive M&A strategy fueled by the financial success of its blockbuster drugs.

The company projects its full-year adjusted profit to be between $35.50 and $36.50 per share. While this range is slightly narrowed from previous guidance ($35.50 to $37 per share), Lilly noted that an increase in underlying profit guidance was offset by charges tied to recent acquisitions.

Shares of Eli Lilly saw a positive reaction, rising 4% in morning trading following the announcement. The company's strong performance and optimistic outlook position it favorably to capitalize on the growing demand for its innovative treatments in the obesity, diabetes, and broader pharmaceutical markets.